ArticleOncoTargets and therapy2024

MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.

Xiang Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.